What is CELC (CELC) stock price today?

CELC (CELC) is currently trading at $91.98, up 3.28% today.

What is CELC P/E ratio?

CELC's P/E ratio is -20.62. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CELC return on equity (ROE)?

CELC's return on equity (ROE) is -350.78%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CELC's market cap?

CELC has a market capitalization of $4.49B.

NASDAQ · Biotechnology

CELC (CELC) Stock

$91.98 +3.28% NASDAQ: CELC Healthcare

Valuation

Metric	Value
Price	$91.98
Market Cap	$4.49B
P/E Ratio	-20.62
P/B Ratio	-379.31
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$151.02
52-Week Low	$44.42
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-350.78%
ROA	-27.35%
ROCE	-28.15%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-59.02
Current Ratio	10.55

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-28.0M	$-39.0M	$-66.0M	$-113.0M	$-172.0M
Net Profit	$-30.0M	$-40.0M	$-64.0M	$-112.0M	$-177.0M
EPS	$-2.28	$-2.68	$-2.69	$-2.83	$-3.78
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$86.0M	$176.0M	$191.0M	$245.0M	$467.0M
Total Liabilities	$17.0M	$42.0M	$51.0M	$130.0M	$366.0M
Cash	$84.0M	$25.0M	$31.0M	$23.0M	$166.0M
Borrowings	$15.0M	$35.0M	$37.0M	$98.0M	$195.0M

Latest News

Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits Investor's Business Daily · Jul 15, 2026 Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval Reuters · Jul 15, 2026 Celcuity gains FDA approval for closely watched breast cancer drug BioPharma Dive · Jul 15, 2026 Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer MarketBeat · Jul 15, 2026 CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug Stocktwits · Jul 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-20.0M	$-36.0M	$-54.0M	$-83.0M	$-153.0M
Investing Cash Flow	$0	$-144.0M	$-5.0M	$-63.0M	$-64.0M
Financing Cash Flow	$0	$0	$50.0M	$16.0M	$0
Net Cash Flow	$73.0M	$-60.0M	$6.0M	$-8.0M	$143.0M
Free Cash Flow	$-20.0M	$-36.0M	$-54.0M	$-84.0M	$-154.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.99
EV / EBITDA	-26.37
FCF Yield	-4.46%
Quick Ratio	8.93
Interest Coverage	-5.95
Return 1Y	61.98%
Return 3Y	843.86%
Return 5Y	320.32%

Ownership

Insiders Held10.03%

Institutions Held101.79%

Institutions Float Held113.13%

Institutional Holder	Shares	Report Date
Baker Bros. Advisors, LP	7,915,792	2026-03-31
Avoro Capital Advisors LLC	3,375,000	2026-03-31
Perceptive Advisors Llc	3,127,200	2026-03-31
RTW Investments LP	3,039,621	2026-03-31
Blackrock Inc.	2,711,532	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPGAscentage Pharma Group International	$20.18	+4.89%	-9.87	$1.88B	0.00%
APGE	$135.08	+0.00%	-16.89	$8.36B	0.00%
CGON	$75.86	+0.93%	-27.84	$6.69B	0.00%
CNTACentessa Pharmaceuticals plc	$40.50	+0.00%	-22.75	$6.27B	0.00%
IRON	$78.67	+0.03%	-11.92	$3.02B	0.00%

About CELC

CELC stock trades at $91.98 with a market capitalization of $4.49B. The stock is valued at a price-to-earnings (P/E) ratio of -20.62, price-to-book of -379.31, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $44.42 and $151.02, and currently trades 39.1% below its 52-week high.

On profitability, CELC generates a return on equity (ROE) of -350.78%, return on capital employed of -28.15%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides